AVEO Pharmaceuticals, Inc. to Present at Upcoming Investment Conferences

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences.

David Johnston, chief financial officer, is scheduled to present at the William Blair 2011 Life Sciences Conference on Wednesday, September 7, 2011 at 2:00 p.m. (EDT) at the InterContinental New York Barclay in New York City.

Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the UBS Global Life Sciences Conference on Monday, September 19, 2011 at 4:30 p.m. (EDT) at the Grand Hyatt in New York City.

Webcasts of AVEO’s presentations can be accessed by visiting the investors section of the company’s website at investor.aveopharma.com. A replay of the webcasts will be archived on the AVEO website for two weeks following each presentation date, respectively.

About AVEO

AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients’ lives. The company’s lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEO’s second most advanced product candidate, ficlatuzumab (AV-299), is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEO’s proprietary Human Response Platform™ is designed to offer the company a unique advantage in cancer drug development and has provided a discovery engine for multiple therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company’s website at www.aveopharma.com.